Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

doi:10.1016/S1473-3099(23)00744-2

. 2024 Feb;24(2):e70-e72.

doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Sijie Yang¹, Yuanling Yu², Yanli Xu³, Fanchong Jian⁴, Weiliang Song⁵, Ayijiang Yisimayi⁵, Peng Wang², Jing Wang², Jingyi Liu⁶, Lingling Yu², Xiao Niu⁵, Jing Wang⁵, Yao Wang², Fei Shao², Ronghua Jin³, Youchun Wang⁷, Yunlong Cao⁸

Affiliations

¹ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁴ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁷ Changping Laboratory, Beijing, China; Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China.
⁸ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 38109919
DOI: 10.1016/S1473-3099(23)00744-2

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Sijie Yang et al. Lancet Infect Dis. 2024 Feb.

. 2024 Feb;24(2):e70-e72.

doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.

Authors

Affiliations

¹ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China; Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing, China.
² Changping Laboratory, Beijing, China.
³ Beijing Ditan Hospital, Capital Medical University, Beijing, China.
⁴ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁵ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁶ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; College of Future Technology, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China.
⁷ Changping Laboratory, Beijing, China; Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China.
⁸ Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China; School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing, China. Electronic address: yunlongcao@pku.edu.cn.

PMID: 38109919
DOI: 10.1016/S1473-3099(23)00744-2

Erratum in

Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2.
[No authors listed] [No authors listed] Lancet Infect Dis. 2024 Mar;24(3):e156. doi: 10.1016/S1473-3099(23)00822-8. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184002 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

YC is the inventor of the provisional patent applications for BD series antibodies, which includes BD55–5514 (SA55). YC is the founder of Singlomics Biopharmaceuticals. All other authors declare no competing interests.

Cited by

Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection.
Zhao XJ, Ji B, Shang C, Li DY, Zhang S, Gu HJ, Peng HH, Qian C, Zhang CL, Shi C, Shen Y, Chen JJ, Xu Q, Lv CL, Jiang BG, Wang H, Li X, Wang GL, Fang LQ. Zhao XJ, et al. iScience. 2024 Jun 15;27(7):110283. doi: 10.1016/j.isci.2024.110283. eCollection 2024 Jul 19. iScience. 2024. PMID: 39040063 Free PMC article.
Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters.
Chen J, Chen C, Yuan L, Chen Y, Wang X, Tang N, Wei D, Ye X, Xia N, Chen Y. Chen J, et al. PNAS Nexus. 2024 May 3;3(5):pgae183. doi: 10.1093/pnasnexus/pgae183. eCollection 2024 May. PNAS Nexus. 2024. PMID: 38800610 Free PMC article.
Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
Raisinghani N, Alshahrani M, Gupta G, Verkhivker G. Raisinghani N, et al. Int J Mol Sci. 2024 Apr 12;25(8):4281. doi: 10.3390/ijms25084281. Int J Mol Sci. 2024. PMID: 38673865 Free PMC article.
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Merdrignac L, et al. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009. Influenza Other Respir Viruses. 2024. PMID: 39523781 Free PMC article.
Conserved role of spike S2 domain N-glycosylation across betacoronaviruses.
Yang Q, Kelkar A, Manicassamy B, Neelamegham S. Yang Q, et al. Npj Viruses. 2025 Jan 25;3(1):4. doi: 10.1038/s44298-024-00085-7. Npj Viruses. 2025. PMID: 40295734 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Affiliations

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

Authors

Affiliations

Erratum in

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous